Cyclosporine — How Dangerous It Is, Side Effects, Kidney Damage, and Consequences of Long-Term Use

EFFECTIVE | TOXIC

Names Under Which Cyclosporine Is Available

The international nonproprietary name is cyclosporine; Latin variants include ciclosporin, cyclosporine, cyclosporin, and ciclosporinum. The names cyclosporine A, ciclosporin A, cyclosporine A, and the abbreviation CsA are also used. Medical documentation may include the abbreviations C0 — the trough concentration measured before the next dose, C2 — the concentration measured two hours after administration, and TDM — therapeutic drug monitoring. Systemic dosage forms include soft gelatin capsules, oral solution, and concentrate for intravenous infusion. Conventional and modified microemulsion formulations differ fundamentally: Sandimmune and Neoral are not bioequivalent and must not be automatically substituted milligram for milligram. The main trade names of systemic cyclosporine include Sandimmune, Sandimmune Neoral, Neoral, Gengraf, and registered generic Cyclosporine Modified products. Ophthalmic formulations are marketed under such names as Restasis, Cequa, Ikervis, Verkazia, and other regional brands; eye drops do not replace systemic immunosuppression. Widely used fixed-dose combinations in which cyclosporine is combined with another active ingredient in the same tablet or capsule are virtually nonexistent. However, dangerous duplication may occur when a systemic formulation, an intravenous preparation, and an incorrectly substituted modified or unmodified formulation are prescribed at the same time.

Why Cyclosporine Is Considered a Manageable Drug and Where the Real Risk Begins

Cyclosporine is often perceived as a long-established and therefore predictable immunosuppressant. This is a dangerous oversimplification. Even at recommended doses, the drug can cause systemic arterial hypertension and nephrotoxicity, with the risk increasing with both dose and duration of treatment. Therapeutic and toxic exposure levels are relatively close to one another, and drug concentrations depend not only on the administered dose but also on the formulation, liver function, food intake, CYP3A4 and P-glycoprotein activity, concomitant medications, and herbal products. An error when switching from Sandimmune to Neoral, the addition of a CYP3A4 inhibitor, or the use of a common pain reliever from the NSAID group can turn a stable regimen into a nephrotoxic one without any obvious change in the cyclosporine dose. The first manifestations — headache, tremor, weakness, increased blood pressure, nausea, or a slight rise in creatinine — are nonspecific and are often incorrectly attributed to the underlying disease, stress, or other medications.

Immunosuppression creates a separate layer of risk: susceptibility to bacterial, viral, fungal, and opportunistic infections increases, and prolonged use raises the likelihood of lymphoproliferative disorders and malignant skin tumors. These are not random complications but a direct consequence of suppression of T-cell immune surveillance. In patients with psoriasis, the risk is especially increased after previous PUVA therapy, UVB exposure, methotrexate, other immunosuppressants, or radiation therapy.

Side Effects During the First Hours, Days, and Weeks of Treatment

In the short term, the most characteristic effects include increased blood pressure, reversible reduction in renal filtration, elevated serum creatinine and urea, tremor, headache, paresthesia, nausea, vomiting, diarrhea, abdominal discomfort, fatigue, hypertrichosis, and gum tenderness or hyperplasia. Hyperkalemia, hypomagnesemia, and hyperuricemia may occur. These changes can develop before any marked deterioration in well-being, so the absence of complaints does not confirm that the dose is safe. The main commonly reported adverse reactions to systemic cyclosporine are renal dysfunction, tremor, hypertrichosis, hypertension, and gingival hyperplasia.

Clinically significant early complications include severe arterial hypertension, acute kidney injury, hyperkalemia with a risk of conduction disturbances, marked elevation of liver function tests, neurotoxicity, severe infections, and drug-induced myopathy resulting from interactions with statins or colchicine. Intravenous administration carries an additional risk associated with polyoxyethylated castor oil in the concentrate: severe anaphylactoid reactions may occur, particularly in patients with hypersensitivity to this solvent.

Rare but life-threatening reactions include seizures, confusion, encephalopathy, posterior reversible encephalopathy syndrome, severe hepatotoxicity, thrombotic microangiopathy, hemolytic uremic syndrome, severe opportunistic infections, and progressive multifocal leukoencephalopathy associated with JC virus. BK virus nephropathy can damage a transplanted kidney and result in graft loss.

Side Effects With Long-Term and Repeated Use

The principal cumulative toxicity of cyclosporine is chronic kidney damage. Early in treatment, functional constriction of the renal arterioles and reduced glomerular filtration predominate and may partially reverse after dose adjustment. With prolonged exposure, structural changes develop, including arteriolar hyalinosis, tubular atrophy, and interstitial fibrosis. At this stage, reducing the drug concentration no longer guarantees full recovery of renal function. Nephrotoxicity may progress slowly, without pain or a sharp decrease in urine output, and may manifest only as persistently elevated creatinine, reduced estimated glomerular filtration rate, hyperkalemia, hypomagnesemia, and arterial hypertension.

Prolonged vasoconstriction and sodium retention sustain arterial hypertension and increase cardiovascular workload. Hyperlipidemia, elevated uric acid, and gout attacks may occur. Gingival hyperplasia can become pronounced, particularly when nifedipine is used concurrently. Hypertrichosis, tremor, and neurological symptoms may persist throughout treatment. Hepatic abnormalities are more often limited to elevations in bilirubin and liver enzymes, but cholestasis, jaundice, hepatitis, liver failure, and rare fatal outcomes have also been reported.

Prolonged immunosuppression increases the risk of reactivation of latent infections, opportunistic infections, lymphomas, and malignant skin tumors. The risk is determined not only by cyclosporine but also by the total immunosuppressive burden from glucocorticosteroids, antimetabolites, biologic agents, previous phototherapy, and radiation exposure. Cyclosporine does not cause physical drug dependence, but abrupt discontinuation can lead to recurrence of autoimmune inflammation, a severe psoriasis relapse, or, after transplantation, an immune attack on the graft. In psoriasis, progression to erythrodermic or generalized pustular forms has been described after dose reduction or withdrawal.

Contraindications and High-Risk Groups

An absolute contraindication is hypersensitivity to cyclosporine or to components of the specific formulation. For intravenous Sandimmune, hypersensitivity to polyoxyethylated castor oil is of particular importance. When treating psoriasis or rheumatoid arthritis, systemic cyclosporine should not be prescribed to patients with impaired renal function, uncontrolled arterial hypertension, or malignancy. The situation is different in transplantation: renal dysfunction does not always permit discontinuation of the drug, but it requires especially careful balancing of the risk of rejection against the risk of further kidney damage.

The most vulnerable groups include older patients and people with a pre-existing reduction in glomerular filtration rate, arterial hypertension, hyperkalemia, hypomagnesemia, hyperuricemia, liver disease, active infection, or a history of malignancy. In severe liver disease, cyclosporine clearance decreases, so a standard dose may produce excessive exposure. Dehydration, fever, diarrhea, and insufficient fluid intake intensify renal vasoconstriction and increase the risk of acute kidney injury, especially in the presence of NSAIDs, antibiotics, or diuretics.

Patients with psoriasis who have previously received PUVA, UVB, methotrexate, other immunosuppressants, coal tar preparations, or radiation therapy have an increased risk of skin tumors. Live vaccines are contraindicated or should be avoided during cyclosporine therapy: the immune response may be inadequate, and the vaccine organism may cause an infectious process. Inactivated vaccines do not carry this risk, but their effectiveness may be reduced.

Dangerous Drug, Food, and Herbal Interactions

Contraindicated or should be avoided. Concomitant use with tacrolimus produces marked nephrotoxic synergy and competitive interaction through CYP3A4 and P-glycoprotein. Hypericum perforatum induces cyclosporine metabolism and transport, lowering its concentration and creating a risk of loss of immunosuppressive effect and graft rejection. Combinations with dabigatran and aliskiren are not recommended because inhibition of P-glycoprotein may substantially increase their systemic exposure. Simvastatin and lovastatin, as well as high doses of other statins, can accumulate and lead to myopathy, rhabdomyolysis, and secondary kidney injury.

Highly undesirable. Aminoglycosides, amphotericin B, vancomycin, trimethoprim-sulfamethoxazole, ciprofloxacin, melphalan, methotrexate, fibrates, and NSAIDs increase nephrotoxicity. Diclofenac, naproxen, and other NSAIDs are particularly dangerous during dehydration because renal blood flow is simultaneously reduced while cyclosporine exerts a stronger effect on the renal arterioles. Potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers, potassium preparations, and potassium-containing salt substitutes increase the risk of hyperkalemia.

Requires dose adjustment and concentration monitoring. Macrolides, azole antifungal agents, diltiazem, verapamil, amiodarone, danazol, imatinib, and other inhibitors of CYP3A4 or P-glycoprotein can increase cyclosporine concentrations. Rifampicin, carbamazepine, oxcarbazepine, phenytoin, barbiturates, orlistat, terbinafine, bosentan, and other inducers or drugs that impair absorption can reduce its exposure. Grapefruit and grapefruit juice increase the bioavailability of cyclosporine and should be avoided. Alcohol is not a specific inhibitor of cyclosporine, but it increases variability in blood pressure, dehydration, and hepatic burden; moreover, some cyclosporine solutions already contain ethanol.

Cyclosporine itself inhibits CYP3A4, P-glycoprotein, and OATP transporters and therefore can increase the concentrations of digoxin, colchicine, statins, etoposide, sirolimus, everolimus, and several other drugs. Severe digitalis toxicity has been described within the first days of concomitant treatment with digoxin. Combination with colchicine increases the risk of neuromyopathy and rhabdomyolysis. Concomitant nifedipine use increases gingival hyperplasia.

Patient Errors That Turn Treatment Into Toxic Exposure

The most dangerous mistake is independently switching from one cyclosporine formulation to another. Modified microemulsion and unmodified products have different bioavailability; the same number of milligrams does not mean the same exposure. Switching among Neoral, Sandimmune, and generic formulations requires monitoring of drug concentration, renal function, and clinical response. Irregular administration in relation to food is also an error: cyclosporine should be taken at the same time each day and consistently in relation to meals because variability in absorption makes concentration results more difficult to interpret.

Patients often take ibuprofen, diclofenac, naproxen, or a combination analgesic without considering them a significant part of the treatment regimen. During cyclosporine therapy, even such an episode can accelerate the rise in creatinine, especially during hot weather, diarrhea, fever, or inadequate fluid intake. Other typical errors include consuming grapefruit, taking St. John’s wort “for nerves,” using potassium-containing supplements, sports electrolyte products, salt substitutes, statins without dose adjustment, and antibiotics without consideration of CYP3A4 interactions.

The dose must not be increased during an exacerbation of psoriasis, arthritis, or another disease without measuring cyclosporine concentration and assessing renal function. Lack of a rapid clinical effect does not mean that the dose is inadequate: increased exposure may manifest as nephrotoxicity before immunosuppression becomes stronger. Missed doses followed by a double dose are equally dangerous. Abrupt self-discontinuation because of tremor, increased blood pressure, or rising creatinine is also unacceptable after transplantation: the patient may replace controlled toxicity with uncontrolled organ rejection.

Cyclosporine Overdose and Poisoning

There is no universal single “toxic dose” of cyclosporine that applies equally to all patients. Toxicity depends on the formulation, route of administration, body weight, liver function, interactions, and baseline renal status. Official information describes ingestion of doses up to 10 g, approximately 150 mg/kg, accompanied by vomiting, drowsiness, headache, tachycardia, and moderately severe reversible renal dysfunction. This observation must not be interpreted as a safe threshold: severe poisoning can occur at a substantially lower dose in a patient with liver failure, dehydration, nephropathy, or concomitant use of CYP3A4 inhibitors. Accidental intravenous overdose is particularly dangerous and has been associated with severe consequences.

During the first hours, nausea, vomiting, headache, drowsiness, dizziness, tremor, tachycardia, and increased blood pressure may occur. This may be followed by elevated creatinine and urea, hyperkalemia, hypomagnesemia, reduced urine output, and increased bilirubin and liver enzymes. Severe neurotoxicity may manifest as confusion, visual disturbances, seizures, and encephalopathy. Hidden overdose more often occurs not after intentional ingestion of a large number of capsules but after switching formulations, taking a double dose, or adding clarithromycin, an azole antifungal, diltiazem, grapefruit, or another metabolic inhibitor.

There is no specific antidote. Measures to reduce absorption may be considered during the first hours after ingestion of a large dose, but they are performed in a medical facility. Cyclosporine is virtually not removed by hemodialysis and is poorly removed by charcoal hemoperfusion. Treatment is based on stopping further drug exposure, monitoring vital functions, blood pressure, ECG, urine output, creatinine, urea, electrolytes, liver parameters, and cyclosporine concentration, and correcting complications. Waiting for pronounced symptoms is dangerous: kidney injury and hyperkalemia may worsen despite relatively mild subjective complaints.

Integrative Model With a Lower Toxicological Burden

As a professional pharmacological model for discussion in stable inflammatory and immune-mediated conditions, a combination of Millettia erythrocalyx, standardized 10% extract, Sphaeranthus indicus, Scutellaria baicalensis, and Curcuma longa may be considered. This model is not a herbal analogue of cyclosporine and does not reproduce its direct inhibition of calcineurin followed by suppression of NFAT activation and interleukin-2 synthesis. Its purpose is different: to influence several pathways of chronic inflammation without producing such pronounced systemic T-cell immunosuppression and the associated nephrotoxic, infectious, and oncological burden.

Millettia erythrocalyx, standardized 10% extract is considered the central rare component of the model. Its pharmacological significance is associated with anti-inflammatory and immunoregulatory activity, the potential limitation of excessive production of pro-inflammatory mediators, and reduction of inflammatory activity in tissues. In this model, it does not mechanistically replace cyclosporine but forms the basis of a gentler, multitarget approach that may be discussed in chronic dermatological, articular, and other stable inflammatory phenotypes.

Sphaeranthus indicus complements the model with an anti-inflammatory, antiallergic, and immunoregulatory profile. Its role is most logical in dermatological conditions accompanied by itching, skin hyperreactivity, chronic inflammatory infiltration, and a relapsing course. Unlike cyclosporine, this taxon is not intended for rapid and profound suppression of cellular immunity, so its role is not acute rescue treatment but long-term, multilevel regulation of inflammation.

Scutellaria baicalensis strengthens the anti-inflammatory direction of the model through effects on cytokine activity and intracellular signaling cascades. It is considered a component that limits pathological activation of immune cells but does not create controlled transplant immunosuppression comparable to cyclosporine.

Curcuma longa is used as a background systemic anti-inflammatory component. Its inclusion is intended to reduce inflammatory reactions in tissues and support broader control of chronic inflammation. Curcuma zedoaria and Curcuma aromatica may be of pharmacological interest in other models, but for the present objective Curcuma longa has a more comprehensive systemic profile.

In prolonged disease, baseline renal vulnerability, or when additional tissue protection is needed, the model may be discussed with the addition of Rehmannia glutinosa. When articular, intestinal, or leukotriene-dependent inflammation predominates, Boswellia serrata may serve as a more targeted additional component. In an atopic, allergic, or Th2-associated phenotype, professional discussion of Nigella sativa may be appropriate. These components should not be mechanically combined into a single overloaded formula: the composition of the model should correspond to the predominant clinical phenotype.

The herbal model may be discussed in mild or moderate stable inflammatory disease, during maintenance therapy, or as a strategy for gradually reducing the overall pharmacological burden. It cannot be regarded as a complete replacement for cyclosporine after transplantation, when graft rejection is threatened, in severe uveitis with a risk of vision loss, aplastic anemia, a rapidly progressive systemic autoimmune process, or another condition requiring strong, predictable, and rapidly acting immunosuppression. In such situations, reducing or discontinuing cyclosporine without equivalent disease control may lead to irreversible consequences.

Real-World Effectiveness of Cyclosporine and the Limits of Its Capabilities

Cyclosporine is genuinely effective where pathological activation of T lymphocytes poses an immediate threat to an organ, graft, or tissue function. It suppresses calcineurin-dependent T-cell activation, reduces interleukin-2 production, and limits the cellular immune response. For this reason, the drug is used to prevent rejection of transplanted kidneys, livers, and hearts, as well as in certain severe immune-mediated diseases.

In transplantation, cyclosporine does not eliminate the cause of the immunological conflict but continuously suppresses the immune system’s ability to attack the foreign organ. As long as the required exposure is maintained, the risk of rejection is reduced; if the concentration becomes insufficient or treatment is abruptly discontinued, the immune attack may resume. Therefore, the drug’s effectiveness is inseparable from long-term monitoring of concentration, graft function, interactions, and the total level of immunosuppression.

In severe psoriasis, cyclosporine can reduce inflammation and the affected skin area relatively quickly, but the achieved effect usually persists only while treatment continues. After therapy is stopped, the improvement may disappear because the drug does not eliminate the underlying pathogenetic predisposition to the disease.

In rheumatoid arthritis, the drug may reduce inflammatory activity in patients who have had an inadequate response to other therapy, but its use is limited by nephrotoxicity, arterial hypertension, and the need for regular monitoring.

A typical medical error is to prescribe cyclosporine as an ordinary long-term anti-inflammatory drug without first defining the treatment goal, criteria for effectiveness, acceptable duration of therapy, and conditions for discontinuation. It is equally dangerous to assess safety solely according to how the patient feels. A normal subjective condition does not exclude reduced glomerular filtration, hyperkalemia, increased blood pressure, or excessive drug exposure.

Other errors include failure to assess baseline renal function and blood pressure, continuation of treatment despite a persistent increase in creatinine, disregard for drug interactions, automatic substitution of an original or unmodified formulation with a microemulsion formulation, and concomitant prescription of nephrotoxic agents without intensified monitoring. Different cyclosporine formulations should not be considered automatically interchangeable.

Safety Monitoring During Treatment

Before systemic treatment is started, baseline parameters must be established against which toxicity can subsequently be assessed: blood pressure, serum creatinine, estimated glomerular filtration rate, urea, potassium, magnesium, uric acid, bilirubin, and liver enzyme activity. Depending on the indication, a complete blood count, lipid profile, signs of active infection, history of malignancy, skin status, and concomitant immunosuppressive therapy are also assessed.

At the beginning of treatment, after changing the dose or formulation, or after adding a potentially interacting drug, renal function and blood pressure are monitored more frequently. After switching between cyclosporine products, it is particularly important to monitor renal function, blood pressure, and tolerability during the first weeks.

In transplant recipients, therapeutic drug monitoring is an important part of treatment. The trough concentration immediately before the next dose, C0, is used, or in some protocols the concentration two hours after administration, C2. A universal target range cannot be established: it depends on the transplanted organ, time since transplantation, concomitant immunosuppression, rejection risk, and the laboratory method used.

When psoriasis or rheumatoid arthritis is treated, blood cyclosporine concentration does not always correlate well with clinical effect or toxicity, so measuring the drug level does not replace monitoring of creatinine and blood pressure.

Repeated elevation of creatinine, a substantial reduction in estimated glomerular filtration rate, persistent hyperkalemia, uncontrolled elevation of blood pressure, pronounced tremor, worsening headache, visual impairment, confusion, or seizures require immediate assessment of exposure and review of therapy.

Emergency warning signs include a sharp reduction in urine output, rapidly increasing edema, severe shortness of breath, arrhythmias associated with hyperkalemia, seizures, sudden worsening of vision, altered consciousness, severe headache accompanied by hypertension, jaundice, fever with signs of systemic infection, unusual neurological disturbances, and an anaphylactoid reaction during intravenous administration. Waiting in these situations is dangerous because acute nephrotoxicity, encephalopathy, severe infection, or electrolyte disturbances can progress faster than specific symptoms appear.

Correct Discontinuation of Cyclosporine and Consequences of Stopping Treatment

Cyclosporine does not cause classic physical dependence or a specific universal withdrawal syndrome comparable to glucocorticosteroid withdrawal. However, this does not mean that the drug can be stopped arbitrarily. The main risk is not withdrawal itself but the return of the immune activity that the drug had been suppressing.

After transplantation, abrupt discontinuation or missed doses can reduce immunosuppressive protection and provoke acute or chronic rejection. In this situation, cyclosporine must not be independently replaced with herbal preparations, dietary supplements, or another immunomodulator. Any change must be made within an agreed immunosuppressive regimen, taking pharmacokinetics, graft function, and drug concentration into account.

In psoriasis and other inflammatory diseases, the dose is usually reduced gradually while clinical activity is assessed at the same time. Discontinuation that is too rapid can lead to relapse and sometimes to a more severe exacerbation. Improvement of the skin itself does not mean that the disease has been eliminated: stopping cyclosporine is often followed by loss of the achieved effect.

If discontinuation is required because of nephrotoxicity, hypertension, infection, or neurotoxicity, the rate of regimen modification is determined by the severity of the complication. In life-threatening toxicity, the drug may need to be discontinued more rapidly, but control of the underlying disease or prevention of rejection must simultaneously be maintained with alternative therapy.

Transition to an integrative model may be discussed only in a stable non-transplant setting when the severity of the disease allows the pharmacological burden to be reduced gradually. Herbal components should not be introduced in large numbers at the same time; otherwise, it becomes impossible to determine tolerability, interactions, and the actual effect of each component.

A Rational Approach to Cyclosporine Use

Cyclosporine is justified when strong, relatively rapid, and predictable immunosuppression is required: after transplantation, when there is a threat of irreversible organ damage, in severe immune-mediated disease, or when safer approaches have failed. In these situations, its toxicity does not make the drug ineffective — it defines the cost of its effect and the need for strict monitoring.

The drug becomes unjustifiably dangerous when it is prescribed for moderate stable inflammation without a clearly defined goal, used longer than necessary, continued despite progressive nephrotoxicity, or combined with interacting agents without laboratory monitoring. Cyclosporine can cause arterial hypertension and kidney damage even at recommended doses, and the risk increases with both dose and duration of treatment.

In a mild or moderate stable non-transplant inflammatory condition, a pharmacological model based on Millettia erythrocalyx 10%, Sphaeranthus indicus, Scutellaria baicalensis, and Curcuma longa, adapted to the predominant inflammatory phenotype, may be discussed. Its purpose is not to imitate cyclosporine but to reduce pathological inflammatory activity with a lower likelihood of pronounced nephrotoxicity, severe immunosuppression, and infectious complications.

Concomitant use of cyclosporine with herbal components requires particular caution. Any extract capable of altering CYP3A4, P-glycoprotein, blood pressure, potassium levels, liver function, or kidney function could theoretically change cyclosporine exposure and toxicity. Therefore, the integrative model should be regarded as an independent professional concept or as a controlled adjunct, rather than as a collection of extracts added arbitrarily to existing immunosuppression.

A rational strategy is not to oppose synthetic and herbal pharmacology but to select the necessary strength of intervention. When saving a graft or organ is required, cyclosporine may be indispensable. When the disease is stable and permits gentler control, it is reasonable to discuss reducing the toxicological burden and transitioning to a multitarget anti-inflammatory model.

If you have questions about the topic of this article, you can ask a clinical pharmacologist in the comments or schedule an appointment via the following link: https://asiabiopharm.com/konsultaciii/